Corporate ActionMay 27, 2026, 04:46 PM
Artelo Biosciences Establishes $6.53M At-The-Market Equity Program
AI Summary
Artelo Biosciences, Inc. has entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC to sell up to $6,530,000 of its common stock. This program allows the company to raise capital from time to time, with the sales agent receiving a 3.0% commission on gross sales. Separately, Craft Capital Management LLC has filed a FINRA arbitration claim against Artelo Biosciences, seeking $880,000 in success fees and $880,000 in common stock warrants, alleging a breach of contract related to a prior $11 million private placement.
Key Highlights
- Artelo Biosciences established an At The Market (ATM) equity program to sell up to $6,530,000 of common stock.
- H.C. Wainwright & Co., LLC will act as the sales agent for the ATM offering.
- The sales agent will receive a commission of 3.0% of the gross sales price per share.
- Craft Capital Management LLC filed a FINRA arbitration claim against the company.
- Craft Capital is seeking an $880,000 success fee and common stock warrants valued at $880,000.
- The claim alleges breach of a right of first refusal related to an $11 million private placement.
- The ATM offering will be effected pursuant to an effective shelf registration statement on Form S-3.
Price Impact
More from ARTL